698 related articles for article (PubMed ID: 32564775)
21. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
[TBL] [Abstract][Full Text] [Related]
22. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
[TBL] [Abstract][Full Text] [Related]
23. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2017 Feb; 92(2):209-217. PubMed ID: 28094456
[TBL] [Abstract][Full Text] [Related]
24. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.
Varettoni M; Zibellini S; Defrancesco I; Ferretti VV; Rizzo E; Malcovati L; Gallì A; Porta MGD; Boveri E; Arcaini L; Candido C; Paulli M; Cazzola M
Haematologica; 2017 Dec; 102(12):2077-2085. PubMed ID: 28983055
[TBL] [Abstract][Full Text] [Related]
25. Simple headache revealed a rare lymphoma: Waldenstrom macroglobulinemia with unique markers: a case report and review of the literature.
Awad AK; Elbadawy MA; Boury M; Rivera A; Motawea K; Shah J; Parnia S; Varney J
J Egypt Natl Canc Inst; 2022 Mar; 34(1):10. PubMed ID: 35253074
[TBL] [Abstract][Full Text] [Related]
26. Waldenström macroglobulinemia: my way.
Gertz M
Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
[TBL] [Abstract][Full Text] [Related]
27. How I treat Waldenström macroglobulinemia.
Treon SP
Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
[TBL] [Abstract][Full Text] [Related]
28. Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.
Higgins L; Nasr SH; Said SM; Kapoor P; Dingli D; King RL; Rajkumar SV; Kyle RA; Kourelis T; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Ansell SM; Gonsalves WI; Thompson CA; Fervenza FC; Zand L; Hwa YL; Jevremovic D; Shi M; Leung N
Clin J Am Soc Nephrol; 2018 Jul; 13(7):1037-1046. PubMed ID: 29848505
[TBL] [Abstract][Full Text] [Related]
29. IgM Plasma Cell Myeloma.
Lu H; Durkin L; Zhao X; Nakashima MO
Am J Clin Pathol; 2022 Jan; 157(1):47-53. PubMed ID: 34508562
[TBL] [Abstract][Full Text] [Related]
30. Beyond monoclonal gammopathy of undetermined significance, clinical spectrum of immunoglobulin M gammopathy: a case series with focus on the diagnostic and management challenges.
Ashruf OS; Mirzai S; George LL; Anwer F
Int J Hematol Oncol; 2023 Jun; 12(2):IJH44. PubMed ID: 37304326
[TBL] [Abstract][Full Text] [Related]
31. IgM myeloma: a report of four cases.
Dierlamm T; Laack E; Dierlamm J; Fiedler W; Hossfeld DK
Ann Hematol; 2002 Mar; 81(3):136-9. PubMed ID: 11904738
[TBL] [Abstract][Full Text] [Related]
32. Concomitant Waldenstrom macroglobulinemia and IgA plasmablastic myeloma in a patient with untreated IgM paraproteinemia: sequential development of biclonal B-cell neoplasms over a 10-year period in a single individual.
Wang E; Kulbacki E; Stoecker M
Hum Pathol; 2012 Jul; 43(7):1135-41. PubMed ID: 22404949
[TBL] [Abstract][Full Text] [Related]
33. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
Kapoor P; Paludo J; Ansell SM
Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
[TBL] [Abstract][Full Text] [Related]
34. Waldenström macroglobulinemia.
Gertz MA
Hematology; 2012 Apr; 17 Suppl 1():S112-6. PubMed ID: 22507796
[TBL] [Abstract][Full Text] [Related]
35. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders.
Ondrejka SL; Lin JJ; Warden DW; Durkin L; Cook JR; Hsi ED
Am J Clin Pathol; 2013 Sep; 140(3):387-94. PubMed ID: 23955458
[TBL] [Abstract][Full Text] [Related]
36. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2023 Feb; 98(2):348-358. PubMed ID: 36588395
[TBL] [Abstract][Full Text] [Related]
37. IgM multiple myeloma: report of four cases and review of the literature.
Annibali O; Petrucci MT; Del Bianco P; Gallucci C; Levi A; Foà R; Avvisati G
Leuk Lymphoma; 2006 Aug; 47(8):1565-9. PubMed ID: 16966268
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.
Cohen C; Royer B; Javaugue V; Szalat R; El Karoui K; Caulier A; Knebelmann B; Jaccard A; Chevret S; Touchard G; Fermand JP; Arnulf B; Bridoux F
Kidney Int; 2015 Nov; 88(5):1135-43. PubMed ID: 26176826
[TBL] [Abstract][Full Text] [Related]
39. [IgM myeloma: 6 cases and a review of the literature].
De Gramont A; Grosbois B; Michaux JL; Peny AM; Pollet JP; Smadja N; Krulik M; Debray J; Bernard JF; Monconduit M
Rev Med Interne; 1990; 11(1):13-8. PubMed ID: 2109345
[TBL] [Abstract][Full Text] [Related]
40. Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2021 Feb; 96(2):258-269. PubMed ID: 33368476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
